Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3315148
Max Phase: Preclinical
Molecular Formula: C52H66Cl2N10O11S2
Molecular Weight: 1142.20
Molecule Type: Protein
Associated Items:
ID: ALA3315148
Max Phase: Preclinical
Molecular Formula: C52H66Cl2N10O11S2
Molecular Weight: 1142.20
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(Cl)c(Cl)c2)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C52H66Cl2N10O11S2/c1-27(2)42(51(74)75)63-49(72)40-26-76-77-52(3,4)43(64-44(67)34(56)24-41(65)66)50(73)61-37(21-28-12-6-5-7-13-28)46(69)60-39(23-30-25-57-35-15-9-8-14-31(30)35)48(71)58-36(16-10-11-19-55)45(68)59-38(47(70)62-40)22-29-17-18-32(53)33(54)20-29/h5-9,12-15,17-18,20,25,27,34,36-40,42-43,57H,10-11,16,19,21-24,26,55-56H2,1-4H3,(H,58,71)(H,59,68)(H,60,69)(H,61,73)(H,62,70)(H,63,72)(H,64,67)(H,65,66)(H,74,75)/t34-,36-,37-,38-,39-,40-,42-,43+/m0/s1
Standard InChI Key: IUBDXYQIJVKBAW-FLECMKQLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1142.20 | Molecular Weight (Monoisotopic): 1140.3731 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.. (2014) Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor., 57 (14): [PMID:24992374] [10.1021/jm500218x] |
Source(1):